Correspondence on “Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab”by Graser et al
Saved in:
| Main Authors: | Liwen Zhang, Mingzhu Gao, Jinyou Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/6/e012582.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab
by: Guru Sonpavde, et al.
Published: (2025-05-01) -
Response to: Correspondence on “Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab” by Gao et al
by: Guru Sonpavde, et al.
Published: (2025-06-01) -
Predicting atezolizumab response in metastatic urothelial carcinoma patients using machine learning on integrated tumour gene expression and clinical data
by: Chayanit Piyawajanusorn, et al.
Published: (2025-06-01) -
Efficacy and safety of atezolizumab in the treatment of urothelial carcinoma: a systematic review and meta-analysis
by: Jun Xie, et al.
Published: (2025-04-01) -
Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
by: Wei Chen, et al.
Published: (2025-01-01)